OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars

New Delhi: OneSource Specialty Pharma Ltd on Tuesday announced a manufacturing partnership for biosimilars with Munich-based Formycon AG, an independent biosimilar developer.

Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its biologics' facility in Bengaluru, the company said in a statement.

"This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide," OneSource Specialty Pharma Managing Director & CEO Neeraj Sharma said.


Also read: FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

He further said, "It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics."

Formycon AG CEO Stefan Glombitza said, "By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency."

"We aim to broaden sustainable global access to life-changing biosimilar therapies, " said Glombitza.